Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

20

Revenue 2017

Triumeq

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Triumeq was produced by GlaxoSmithKline.

Choices, choices: the rapidly evolving HIV treatment landscape

Choices, choices: the rapidly evolving HIV treatment landscape As the first non-Gilead STR, it will be interesting to see how Triumeq affects the more established STRs. ... Although Atripla and Eviplera contain NNRTIs, both of the newer products – Stribild and Triumeq – contain IIs.

GSK replaces head of US operations

GSK replaces head of US operations drugs Triumeq and Tivicay by 2018 and $1.4bn for its shingles vaccine HZ/su.

Germany gives green light to Viiv's Triumeq for HIV

Germany gives green light to Viiv's Triumeq for HIV Triumeq combines ViiV's antiretroviral stalwarts lamivudine and abacavir with its new integrase inhibitor Tivicay (dolutegravir), which was backed by IQWIG last year. ... month. Treatment-naïve patients make up the largest target population for Triumeq,

Cancer drugs lead SMC recommendations

Cancer drugs lead SMC recommendations Triumeq is a combination of dolutegravir, abacavir and lamivudine developed by ViiV Healthcare, a partnership between Pfizer, GSK and Shionogi.

GSK to sell off part of its HIV venture ViiV Healthcare

GSK to sell off part of its HIV venture ViiV Healthcare The firm can expect a further boost from the recently-launched Triumeq, which gained approval from the US FDA in August and was licensed in the EU in September. ... GSK's CEO Andrew Witty said ViiV had made “very significant progress in both R&D and

[ Previous 5 results ] 2 3 4 5 6 7 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics